On September 26th, Pfizer Investment Co., Ltd. (Pfizer) and Shangyao Holdings Co., Ltd. (Shangyao Holdings) signed a strategic cooperation framework agreement. The two parties will focus on the vaccine field and carry out long-term cooperation in product promotion, innovative product introduction, and policy research. Based on their respective advantages, we will explore strategic partnerships to deepen the commercial promotion of upgraded vaccine products, accelerate the introduction of innovative products, and deepen cooperation in policy research and capacity training, in order to support the vigorous development of China's medical public health service industry and disease control, and better assist in disease prevention and health improvement for people at all stages of life.
Jean Christophe Pointeau, President of Pfizer China, said, "This strong partnership between Pfizer and Commercial Holdings will leverage their respective strengths to scientifically empower the promotion and popularization of innovative vaccines, enabling internationally leading innovative vaccines to benefit more Chinese people, comprehensively improve the health level of the nation, and become another new quality productivity in the reform of the disease control system, contributing to the achievement of the 'Healthy China 2030' strategic goal
Under the guidance of favorable policies, the domestic biopharmaceutical industry has entered the 'fast lane' of development and achieved all-round development. We are pleased to work together with Pfizer to further improve the coverage and accessibility of innovative vaccines, enhance the quality of life cycle immunization services, and realize a new format of preventive immunization health services that is fair, accessible, systematic, and sustainable, benefiting more Chinese patients and supporting the reform of China's medical system and the development of public health